Better patient counseling needed on post-RP erectile function

Article

There appears to be a substantial difference between what patient expectation of recovery of erectile function following radical prostatectomy and what they actually experience.

There appears to be a substantial difference between what patients expect of recovery of erectile function following radical prostatectomy and what they actually experience.

The difference may put severe strain on physician-patient relationships, say researchers from Memorial Sloan-Kettering Cancer Center, New York.

First author Christian J. Nelson, PhD, reported yesterday that only 13% of men with erections sufficient for penetration before the procedure returned to that status without using medications such as phosphodiesterase type-5 inhibitors. Dr. Nelson stressed the need for appropriate pre-procedure counseling.

"It is better to give patients this information before the procedure than to try to explain it to them following the procedure," Dr. Nelson told Urology Times. He acknowledged that much of the published literature reports significantly higher recovery rates, some as high as 90%.

Acting on anecdotal evidence, Dr. Nelson and his co-authors, Peter Scardino, MD, and John P. Mulhall, MD, assessed the erectile function of 250 men (average age, 59±8 years) pre- and post-radical prostatectomy. Of the men with baseline erectile function scores ≥24 (mild to no dysfunction), about one-third (32%) regained function; however, well over half (60%) required medication to do so. Only 13% of men reporting mild to no dysfunction prior to prostatectomy reported returning to full baseline function at 24 months without medication.

Dr. Nelson stressed that these findings should be clarified with patients prior to the procedure. He observed that prior to undergoing radical prostatectomy, patients were focused on their cancer, and paid little attention to the operation’s side effects. Following the procedure, when the idea of cancer no longer occupied their minds, they would begin to express disappointment about their erectile function.

He also noted that information on the Internet and from marketing presentations of nerve-sparing procedures tended to inflate recovery of function rates.

Related Videos
Kevin M. Wymer, MD
Video 7 - "Multidisciplinary Collaboration and Expert Insights in the Management of Advanced Prostate Cancer"
Video 6 - "Emerging AR Targeting Agents and CDK4/6 Inhibitors in Metastatic Prostate Cancer and Potential Impact on the Treatment Landscape"
Video 5 - "Targeting the Androgen Receptor Pathway and Overcoming Treatment Resistance in Advanced Prostate Cancer"
Video 4 - "Androgen Receptor Signaling and Its Role in Driving Prostate Cancer Metastasis"
Video 3 - "Treatment Selection in Metastatic and Castration Resistant Prostate Cancer: Optimizing Outcomes and Preserving Patient Quality of Life"
Video 2 - "Predicting Risk and Guiding Care: Biomarkers & Genetic Testing in Prostate Cancer"
Video 1 - "Metastatic Prostate Cancer: Background and Patient Prognosis"
Related Content
© 2024 MJH Life Sciences

All rights reserved.